Keelung, Taiwan

Chin-Fen Lee


Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 10(Granted Patents)


Location History:

  • Taipei, TW (1998)
  • Keelung, TW (1999)

Company Filing History:


Years Active: 1998-1999

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations of Chin-Fen Lee in Cancer Treatment

Introduction

Chin-Fen Lee is a notable inventor based in Keelung, Taiwan. He has made significant contributions to the field of biotechnology, particularly in the development of compounds for cancer treatment. With a total of 3 patents, his work has the potential to impact the pharmaceutical industry significantly.

Latest Patents

Chin-Fen Lee's latest patents include innovative compounds such as sulfonyl-N-hydroxyguanidine derivatives. These compounds are characterized by a specific formula where X can be arylene, heteroarylene, fused arylene, or fused heteroarylene. The compounds also include various substituents like sulfonyl and lower alkyl groups. Additionally, he has developed polyamine-linked acridine dimers, which are described as potential anti-cancer agents. These advancements highlight his commitment to finding effective treatments for cancer.

Career Highlights

Chin-Fen Lee is associated with the Development Center for Biotechnology, where he continues to work on groundbreaking research. His focus on creating pharmaceutical compositions that can effectively treat cancer showcases his dedication to improving patient outcomes.

Collaborations

Chin-Fen Lee collaborates with esteemed colleagues such as Shan-Shue Wang and Shan-Yen Chou. Their combined expertise contributes to the innovative research being conducted at the Development Center for Biotechnology.

Conclusion

Chin-Fen Lee's contributions to cancer treatment through his patented innovations demonstrate his significant role in the biotechnology field. His work not only advances scientific knowledge but also holds promise for improving therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…